Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Non-Hodgkin Lymphoma (NHL), Cutaneous Lymphoma, Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome
Interventions: Brentuximab vedotin; Drug
Lead sponsor: Youn Kim; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Advanced Esophageal Cancers, Primary Small Cell Lung Cancers, Non-Small-Cell Lung Carcinoma, Pleural Mesotheliomas, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
Interventions: Decitabine, Depsipeptide, Celecoxib; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Complication of Prematurity, Immunologic Deficiency Syndromes
Interventions: Adjuvant, Blood Collection; Other
Lead sponsor: University of Florida; Other
Eligibility: Up to 55 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Engorgement
Interventions: Simplisse Double Electric Breast Pump; Device
Lead sponsor: Foundation for Maternal Infant and Lactation Knowledge; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions: Bicalutamide, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Therapeutic Conventional Surgery, Vorinostat; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 12 more

Conditions: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Interventions: BT5528, Nivolumab; Drug
Lead sponsor: BicycleTx Limited; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: Encinitas, California • Orange, California • Denver, Colorado + 9 more

Conditions: Coronary Artery Disease
Interventions: atrial tissue sample; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Neoplasms
Interventions: FdCyd + THU; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 6
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 3 more

Conditions: Brain Concussion, Mild Traumatic Brain Injury, Headache
Interventions: CRISP (Concussion Recovery and Support Program); Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 18 Years to 29 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma
Interventions: brentuximab vedotin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 19
States / cities: Anaheim, California • Lafayette, Colorado • Pembroke Pines, Florida + 14 more

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, t(9;22)
Interventions: Blinatumomab, Cytarabine, Methotrexate, Ponatinib; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer
Interventions: Mindfulness-based at therapy; Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 21 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Arrhythmias
Interventions: Peripheral blood sampling; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: Not listed
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Streptococcal Pharyngitis
Interventions: Identifying group A strep carriers; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 5 Years to 15 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Cancer
Interventions: Pembrolizumab, Nab-Paclitaxel, Biopsy; Drug · Procedure
Lead sponsor: Adrienne G. Waks; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Eucaloric feeding, Overfeeding; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 20 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab Deruxtecan; Drug
Lead sponsor: Sun Yat-sen University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Conditions: Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma
Interventions: laboratory biomarker analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Monrovia, California

Conditions: Breast Cancer
Interventions: 5-Fluorouracil, Cyclophosphamide, Doxorubicin, Paclitaxel, Epirubicin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Schizophrenia
Interventions: PEAR-004, Sham; Device
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Garden Grove, California • Oakland, California • Torrance, California + 3 more

Conditions: Pheochromocytoma, Paraganglioma
Interventions: [18F]FluorThanatrace ([18F]FTT); Drug
Lead sponsor: Heather Wachtel; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Lahey Clinic; Other
Eligibility: Male only
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2030
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Dyslipidemia
Interventions: Diet; Other
Lead sponsor: Tufts University; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

Novel Mechanisms and Approaches to Treat Neonatal Sepsis

Engorgement Study With a Double Electric Breast Pump

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Expression of Angiogenic Factors in Myocardial Tissue

FdCyd and THU for Advanced Solid Tumors

Concussion Recovery and Support Program

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Mindfulness-Based Art Therapy for Cancer Patients

Ventricular Tachyarrhythmia (VT) Storm, Gene Expression in Implantable Cardioverter Defibrillator (ICD) Patients With Electrical Storm

Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer

GRoup A StrePtococcus

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

White Adipose Tissue Clocks and High Calorie Feeding

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns

Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

Study of Efficacy of PEAR-004 in Schizophrenia

In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma

Aberrant Gene Expression Prostate Carcinoma

Dietary Carbohydrate Type and Cardiovascular Disease (CVD) Risk Indicators